ACUTE kidney injury in cancer patients was tied to heavy drug use and drug interactions in one ICU, a retrospective study finds. Researchers reviewed 210 adults with cancer treated in intensive care units at a tertiary care center. All had received anticancer therapy within 30 days before or during their ICU stay. Acute kidney injury, or AKI, was defined and staged with KDIGO criteria. The team counted each patient’s total drugs and kidney toxic drugs. They also screened for potential drug interactions with a standard database.
Acute Kidney Injury in Cancer Patients: What the Numbers Showed
AKI developed in 86 patients, or 41.0%. These patients took more drugs, with a median of 11 versus 8 (p < 0.001). They also had more potential drug interactions, with a median of 6 versus 3 (p < 0.001).
In an adjusted model, taking 10 or more distinct drugs was linked to higher odds of AKI (aOR 2.62; 95% CI 1.32 to 5.18). So was having at least one potential interaction tied to kidney toxicity (aOR 2.87; 95% CI 1.43 to 5.76). Other independent predictors were a higher APACHE II score (aOR 1.09 per point), chronic kidney disease, sepsis, and cisplatin exposure.
The outcome gap was large. In-hospital mortality was 39.5% in patients with AKI and 21.8% in those without it (p = 0.007).
What Acute Kidney Injury in Cancer Patients Means for Clinicians
The findings suggest that drug count and drug interactions add risk beyond well known factors such as sepsis, kidney disease, and cisplatin. The authors say routine review of medicines by a pharmacist and screening for kidney related interactions may help prevent kidney injury in critically ill patients with cancer.
The study was retrospective and observational. It shows an association, not proof that drug burden or interactions cause AKI. It was also done at a single center, so results may not apply to every ICU.
Reference
Mahadevan L et al. Association of medication burden and potential drug-drug interactions with acute kidney injury among critically ill patients receiving anticancer therapy at a tertiary care centre. J Oncol Pharm Pract. 2026. doi:10.1177/10781552261506996